PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19076835-7	2009	More importantly, in response to mercury a large numbers of ICR (88%), NMRI (96%) and Black Swiss (100%) mice produced different levels of IgG1 and IgG2a ANolA (a characteristic which is linked strictly to the H-2 genes).	Mercury	33-40	immunoglobulin heavy variable V1-9	Mus musculus	148-153	
20976163-3	2010	METHODS AND PRINCIPAL FINDINGS: Mercury treated BALB/c wt mice showed a significant but modest increase of circulating IC (CIC) from day 12 until day 18 and day 35 for IgG2a- and IgG1- CIC, respectively.	Mercury	32-39	immunoglobulin heavy variable V1-9	Mus musculus	168-173	
20976163-4	2010	Mercury-treated mice lacking the trans-membrane gamma-chain of activating FcgammaRs (FcRgamma(-/-)) had significantly higher CIC levels of both IgG1-CIC and IgG2a-CIC than wt mice during the treatment course.	Mercury	0-7	immunoglobulin heavy variable V1-9	Mus musculus	157-162	
15720444-4	2005	While mercury administered prior to the induction phase of CIA exerted little, if any, influence, administration of mercury during the induction phase and following onset aggravated the symptoms of this disease and increased the serum levels of IgE and IgG2a antibodies directed against collagen type II (CII).	Mercury	116-123	immunoglobulin heavy variable V1-9	Mus musculus	253-258	
9764596-7	1998	While mercury-treated IL-4(-/-) H-2S mice had virtually no detectable serum IgG1 or IgE, and very low levels of IgG1 ANoA, these mice had levels of IgG2a and IgG2b class ANoA comparable to mercury-treated IL-4+ H-2S mice, indicating that IL-4 is not required for the ANoA response in mercury-induced autoimmunity.	Mercury	6-13	immunoglobulin heavy variable V1-9	Mus musculus	148-153	
9822261-9	1998	Sera of both mercury- and saline-treated mice immunized with HRBCs showed high titres of specific IgM, IgG1 and IgG2a anti-HRBCs antibodies.	Mercury	13-20	immunoglobulin heavy variable V1-9	Mus musculus	112-117	
9822261-10	1998	Surprisingly, 3-week treatment with mercury induced a reduction in the titres of specific IgG2a anti-HRBCs antibodies in DBA/2 mice after immunization with HRBCs.	Mercury	36-43	immunoglobulin heavy variable V1-9	Mus musculus	90-95	
10233715-9	1999	To further explore the role of Th1/Th2 cytokines in the mercury model, we performed anti-interferon-gamma antibody treatment in IL-4-deficient mice together with mercury treatment and found that the production of IgG2a and IgG3, but not IgG2b, antibodies was downregulated.	Mercury	56-63	immunoglobulin heavy variable V1-9	Mus musculus	213-218	
10233715-9	1999	To further explore the role of Th1/Th2 cytokines in the mercury model, we performed anti-interferon-gamma antibody treatment in IL-4-deficient mice together with mercury treatment and found that the production of IgG2a and IgG3, but not IgG2b, antibodies was downregulated.	Mercury	162-169	immunoglobulin heavy variable V1-9	Mus musculus	213-218	
2534665-5	1989	The mesangial IC-deposits in mercury-treated SJL mice contained significantly more IgG1, but significantly less IgG2a and C3 than the combined mesangial-capillary loop deposits in MRL mice.	Mercury	29-36	immunoglobulin heavy variable V1-9	Mus musculus	112-117